Q BioMed, Inc. (QBIO) is a Commercial Stage Biotech Innovator Delivering Key Treatments for Oncology, Vascular Disease and Viral Therapeutics Including Covid-19
October 24, 2020 (Viz Release) – – Q BioMed, Inc. (OTCQB: QBIO), is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. QBIO is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
– Biotech Acceleration Focused on Licensing and Acquiring New Assets. – Rapid Innovation & Partnerships with Established Bio-Industry Leaders. – FDA Approved Non-Opioid Pain-Med Strontium89 Coming to Global Market. – Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer. – Virus-Agnostic Therapeutic for COVID-19, Influenza, Related Diseases and Future Viral Pandemic Outbreaks.
QBIO aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. QBIO believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets.
QBIO launched its FDA approved, non-opioid drug Strontium89, which relieves bone pain from cancer metastases, in February 2020. Strontium89 is also approved for sale in 21 other countries. The QBIO robust clinical pipeline is expected to produce growing revenues for the company and value infection points for investors.
– Strontium89 Will be Available in September 2020 Through Named Patient Program for Bone Metastases Pain Palliation in EU and Globally
On August 11th QBIO announced launching a Named Patient Program for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection, USP). The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS).
Strontium89 is indicated for the treatment of painful skeletal metastases caused by cancer, and is agnostic of the primary tumor. Common primary tumors that metastasize to the bone include prostate, breast, lung, as well as others. In several multicenter, placebo-controlled trials in cancer patients with pain from bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo. Strontium89 is administered intravenously once every three months and for some patients can reduce or even eliminate the need for opioid analgesics; pain relief lasts from 2 – 5 months in most patients.
Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89. For nearly two years, there has been little to no access to this vital therapy, after manufacturing ceased in December of 2018. QBIO is pleased that the Named Patient Program will ensure immediate global patient access to an important therapy for this patient population. In the meantime, QBIO is actively pursuing full regulatory and marketing approval for Strontium89 in all major markets worldwide.
– Scaled Up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing
On July 22nd QBIO and Chemveda Life Sciences announced continued collaboration on Uttroside-B, a chemotherapeutic that has shown remarkable potential efficacy as a treatment for liver cancer. While focused on its commercial rollout of Strontium89, this drug development program will advance another important asset in the QBIO portfolio towards monetization. The efficacy of Uttroside-B, a potent saponin, against liver cancer was demonstrated in a preclinical study published in the November 2016 issue of Scientific Reports, a Nature journal.
– Partnership to Deliver Virus-Agnostic Therapeutic for COVID-19, Influenza, Related Diseases and Future Viral Pandemic Outbreaks
On June 30th QBIO issued a Shareholder Update Letter which included information on a high potential treatment for critical virus based diseases. Technology partner Mannin Research Inc. (Mannin) was recently granted up to $7.7 million in Europe, which will fund 65 percent of every dollar incurred to advance a portfolio of therapeutic assets for vascular diseases currently in development at Mannin, including: glaucoma, cardiovascular diseases, acute kidney disease, and infectious diseases such as influenza and coronavirus, among others.
Given the urgent need for therapeutics to treat COVID-19, Mannin is rapidly accelerating the time to the first clinical milestone for MAN-19. An Investigational New Drug (IND) application (or similar clinical trial proposal) to regulators are planned for late 2020. It is important to note that the MAN-19 therapeutic is virus-agnostic, which makes it relevant to other viral diseases today like influenza and future viral pandemic outbreaks. Therefore, a successful infectious disease application in COVID-19 would position MAN-19 very well as a potential government stockpile drug for inevitable future pandemics. Furthermore, a successful proof-of-concept clinical trial with MAN-19 in COVID-19 patients would provide the clinical dataset to quickly support the development of therapeutics for other vascular diseases such as sepsis, acute kidney injury, and of course glaucoma. All of these are very large markets with significant potential.
For more information on Q BioMed, Inc. (QBIO) visit: http://QBioMed.com
DISCLAIMER: CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CA is NOT affiliated in any manner with any company mentioned herein. CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CA has been compensated $700.00 for this release and HOLDS NO SHARES OF OTCQB: QBIO or ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.